Skip to main content

Lyon Joseph Douglas's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Oct 4, 2023

Accession no.
0000950170-23-051911
Filed
Oct 4, 2023
Trade date
Oct 2, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $65.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lyon Joseph DouglasCIK 0001817838Officer (Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 2, 2023Common StockMOption exerciseAcquired+2,418$11.35+$27,444.38,272Direct
Oct 2, 2023Common StockSSaleDisposed−2,418$27.25F3−$65,890.55,854Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 2, 2023Common StockMOption exerciseDisposed−2,418$0.00$02,418Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.28. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)